Philippe Aftimos, MD · @aftimosp · X·· 2 days agoScore70
Body
T-DXd is approved in HER2-low & ultra-low HR+/HER2- MBC after it improved outcomes in pivotal ph3 trials.
❓A role for T-DXd in HER2-low/HR+ early breast cancer?
Final resuls from TALENT presented today at #ESMO26 are described & commented by @breastDoktor
#ESMOAmbassadors 👇
183 views · 2 likes · 0 reposts · 1 reply
Conference abstracts
LBA23matched by Proffered paper 1: Breast cancer, early and advanced stage
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO ➡️ https://ow.ly/ZBwi50ZZXLm在 X 查看被引用的帖子
Replies in this thread
- Philippe Aftimos, MD @aftimosp
Results also here #ESMO26 #ESMOAmbassadors
Source: Philippe Aftimos, MD · x.com